<p>一种临床上可靠的线粒体评估，将先进的细胞测试转化为可操作的见解，以优化能量、代谢和个性化表现。</p>
<p>, /PRNewswire/ -- 10X Health System 是一家专注于数据驱动的人类优化的精准健康公司，今天宣布通过与 Verséa Discovery, Inc.的战略合作，推出 10X MitoScreen™，一种先进的线粒体健康评估，利用他们的 mescreenTM 技术。10X MitoScreen™旨在提供对线粒体功能和效率的更深入洞察，以及其在代谢韧性、表现和长期健康优化中的作用，预计将在 2026 年第一季度向从业者和消费者提供。现在，特定个体可以独家提前体验这一突破性的评估。</p>
<p>继续阅读</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null"/></p>
<p>10X Health System 与 Verséa Discovery 合作推出 10X MitoScreen™，这是一种下一代线粒体评估，提供对能量、代谢和表现的更深入洞察。该技术基于在先进研究环境中验证的技术，这一突破将临床上可靠的线粒体智能引入现实世界的健康优化——帮助个人和从业者向上游转向主动、个性化的护理。</p>
<p>线粒体驱动细胞能量和代谢健康，但直到现在，线粒体的测量很少同时具备科学严谨性和现实临床相关性。通过与 Verséa Discovery 的合作，10X Health 正在扩展其精准测试生态系统，推出 10X MitoScreen™，帮助将健康优化从症状管理转向根本原因的理解。</p>
<p>10X MitoScreen™背后的技术最初是在 NASA 双胞胎研究中开发和验证的，这是一项标志性的研究，考察了人类在极端太空条件下的表现、韧性和恢复。这一科学基础使得能够评估线粒体的功能、结构和效率，并提供一种在消费者可接触的测试中罕见的生物可视化水平。</p>
<p>10X MitoScreen™使用简单的指尖血样分析实际线粒体功能和代谢效率的关键方面。该评估评估线粒体健康的多个维度，包括能量生产、代谢平衡、氧化压力和线粒体网络动态，生成一个综合的线粒体档案和评分。</p>
<p>结果提供了线粒体表现和适应能力的结构化概述，可用于建立个人基线、跟踪随时间的变化，并在未来健康优化策略中提供信息，随着额外的解释和基于协议的服务的可用性。</p>
<p>“与 Verséa Discovery 的合作使我们能够扩展对先进生物见解的获取，这曾经仅限于研究环境，”<strong>10X Health System 的联合创始人兼首席执行官 Brandon Dawson</strong> 表示。“通过 10X MitoScreen™，个人和从业者可以更清晰地了解细胞层面发生的事情——解锁更精确和主动的健康优化方法。”</p>
<p>“基于多年的研究，我们的目标是将可测量、可追踪的细胞和线粒体健康带给世界——推动慢性疾病、长寿科学和精英运动表现的进步，”<strong>Verséa Discovery 的联合创始人兼首席执行官 Sean Fetcho</strong> 表示。“我们与 10X Health 的合作将我们的技术整合到更广泛的精准健康生态系统中，确保结果不仅仅是提供信息——而是直接塑造个性化的优化策略。”</p>
<p>10X MitoScreen™将在 2026 年第一季度作为 10X Health System 不断扩展的精准测试组合的一部分提供，支持寻求对人类表现和长寿有更深入洞察的消费者、临床医生和企业合作伙伴。</p>
<p>通过 Verséa Discovery 的 mescreenTM 技术，现在可以提前访问该测试，访问 https://mitoscreen.com</p>
<p><strong>关于 10X HEALTH SYSTEM</strong> 10X Health System 是一家精准健康公司，重新定义人们如何理解、优化和掌控自己的健康。基于没有两个个体是相同的信念，10X Health 用数据驱动的见解取代一刀切的方法，利用先进的基因测试、血液分析和新兴诊断来揭示表现、能量和长期健康结果背后的根本原因。</p>
<p>通过将复杂的生物数据转化为清晰、可操作的营养、补充、生活方式和临床治疗建议，10X Health 使个人和组织能够从反应性护理转向主动、个性化的健康优化。该公司服务于消费者、临床医生和企业合作伙伴，正在建立精准健康的新标准——一个数据获取创造清晰度、自信和对人类表现和长寿产生可衡量影响的标准。</p>
<p><strong>关于 VERSÉA DISCOVERY</strong> Verséa Discovery, Inc.是一家总部位于美国的精准医学公司，开创了细胞和线粒体健康技术。其专有的_mescreen™_技术最初在先进的研究环境中得到验证，现在正在为消费者、诊所和研究机构提供下一代精准健康见解。</p>
<p>照片 - https://mma.prnewswire.com/media/2869561/Partnership.jpg</p>
<p>标志 - https://mma.prnewswire.com/media/2869342/10XHealth_Logo.jpg</p>
<p>来源 10X Health System; Verséa Discovery, Inc</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTI2Jk5ld3NJdGVtSWQ9TE43MDcwMyZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMjYxMTQxUFJfTkVXU19VU1BSX19fX19MTjcwNzAz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTI2Jk5ld3NJdGVtSWQ9TE43MDcwMyZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMjYxMTQxUFJfTkVXU19VU1BSX19fX19MTjcwNzAz"/></p>

<p>10X Health System 与 Verséa Discovery 合作推出了 10X MitoScreen™，这是一种下一代线粒体评估测试。该临床稳健的评估旨在提供对线粒体功能、能量生产和代谢健康的洞察。预计将在 2026 年第一季度上市，允许医生和消费者通过简单的血样跟踪线粒体健康。目前，部分个人可以提前获得该测试。该测试基于在 NASA 双胞胎研究中验证的技术，增强了个性化健康优化策略</p>

<p>A clinically robust mitochondrial assessment that transforms advanced cellular testing into actionable insights for optimized energy, metabolism, and personalized performance.</p>
<div class="lb-trans"><p>一种临床上可靠的线粒体评估，将先进的细胞测试转化为可操作的见解，以优化能量、代谢和个性化表现。</p>
</div><p>, /PRNewswire/ -- 10X Health System, a precision wellness company focused on data-driven human optimization, today announced the addition of 10X MitoScreen™, an advanced mitochondrial health assessment, through a strategic partnership with Verséa Discovery, Inc. leveraging their mescreenTM technology. Designed to provide deeper insight into mitochondrial function &amp; efficiency as well as its role in metabolic resilience, performance, and long-term health optimization, 10X MitoScreen™ will be available in the first quarter of 2026 for both practitioners and consumers. Exclusive early access is now available for select individuals seeking to experience this groundbreaking assessment.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- 10X Health System 是一家专注于数据驱动的人类优化的精准健康公司，今天宣布通过与 Verséa Discovery, Inc.的战略合作，推出 10X MitoScreen™，一种先进的线粒体健康评估，利用他们的 mescreenTM 技术。10X MitoScreen™旨在提供对线粒体功能和效率的更深入洞察，以及其在代谢韧性、表现和长期健康优化中的作用，预计将在 2026 年第一季度向从业者和消费者提供。现在，特定个体可以独家提前体验这一突破性的评估。</p>
</div><p>Continue Reading</p>
<div class="lb-trans"><p>继续阅读</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null" alt="" original-src="https://www.prnewswire.com/news-releases/null"/></p>
<p>10X Health System and Verséa Discovery have partnered to launch 10X MitoScreen™, a next-generation mitochondrial assessment delivering deeper insight into energy, metabolism, and performance. Built on technology validated in advanced research environments, this breakthrough brings clinically robust mitochondrial intelligence into real-world health optimization—helping individuals and practitioners move upstream toward proactive, personalized care.</p>
<div class="lb-trans"><p>10X Health System 与 Verséa Discovery 合作推出 10X MitoScreen™，这是一种下一代线粒体评估，提供对能量、代谢和表现的更深入洞察。该技术基于在先进研究环境中验证的技术，这一突破将临床上可靠的线粒体智能引入现实世界的健康优化——帮助个人和从业者向上游转向主动、个性化的护理。</p>
</div><p>Mitochondria drive cellular energy and metabolic health, yet until now have rarely been measured with both scientific rigor and real-world clinical relevance. Through its partnership with Verséa Discovery, 10X Health is expanding its precision testing ecosystem with 10X MitoScreen™, helping move health optimization upstream from symptom management to root-cause understanding.</p>
<div class="lb-trans"><p>线粒体驱动细胞能量和代谢健康，但直到现在，线粒体的测量很少同时具备科学严谨性和现实临床相关性。通过与 Verséa Discovery 的合作，10X Health 正在扩展其精准测试生态系统，推出 10X MitoScreen™，帮助将健康优化从症状管理转向根本原因的理解。</p>
</div><p>The technology underlying 10X MitoScreen™ was originally developed and validated during the NASA Twins Study, a landmark investigation examining human performance, resilience, and recovery under extreme conditions in space. This scientific foundation enables assessment of mitochondrial function, structure &amp; efficiencies, and provides a level of biologic visibility rarely available in consumer-accessible testing.</p>
<div class="lb-trans"><p>10X MitoScreen™背后的技术最初是在 NASA 双胞胎研究中开发和验证的，这是一项标志性的研究，考察了人类在极端太空条件下的表现、韧性和恢复。这一科学基础使得能够评估线粒体的功能、结构和效率，并提供一种在消费者可接触的测试中罕见的生物可视化水平。</p>
</div><p>10X MitoScreen™ analyzes key aspects of actual mitochondrial function and metabolic efficiency using a simple finger prick blood sample. The assessment evaluates multiple dimensions of mitochondrial health, including energy production, metabolic balance, oxidative stress, and mitochondrial network dynamics, generating an integrated mitochondrial profile and score.</p>
<div class="lb-trans"><p>10X MitoScreen™使用简单的指尖血样分析实际线粒体功能和代谢效率的关键方面。该评估评估线粒体健康的多个维度，包括能量生产、代谢平衡、氧化压力和线粒体网络动态，生成一个综合的线粒体档案和评分。</p>
</div><p>Results provide a structured overview of mitochondrial performance and adaptive capacity and may be used to establish a personal baseline, track changes over time, and inform future health optimization strategies as additional interpretive and protocol-based services become available.</p>
<div class="lb-trans"><p>结果提供了线粒体表现和适应能力的结构化概述，可用于建立个人基线、跟踪随时间的变化，并在未来健康优化策略中提供信息，随着额外的解释和基于协议的服务的可用性。</p>
</div><p>&#34;Partnering with Verséa Discovery allows us to expand access to advanced biological insights that was once limited to research environments,&#34; said <strong>Brandon Dawson, Co-Founder and CEO of 10X Health System</strong>. &#34;With 10X MitoScreen™, individuals and practitioners gain a clearer view of what's happening at the cellular level—unlocking more precise and proactive approaches to health optimization.&#34;</p>
<div class="lb-trans"><p>“与 Verséa Discovery 的合作使我们能够扩展对先进生物见解的获取，这曾经仅限于研究环境，”<strong>10X Health System 的联合创始人兼首席执行官 Brandon Dawson</strong> 表示。“通过 10X MitoScreen™，个人和从业者可以更清晰地了解细胞层面发生的事情——解锁更精确和主动的健康优化方法。”</p>
</div><p>&#34;Built on years of research, our purpose is to bring measurable, trackable cellular and mitochondrial health to the world—fueling progress in chronic disease, longevity science, and elite athletic performance,&#34; said <strong>Sean Fetcho, Co-Founder and CEO of Verséa Discovery</strong>. &#34;Our partnership with 10X Health integrates our technology into a broader precision health ecosystem, ensuring results don't merely inform—but directly shape personalized optimization strategies.&#34;</p>
<div class="lb-trans"><p>“基于多年的研究，我们的目标是将可测量、可追踪的细胞和线粒体健康带给世界——推动慢性疾病、长寿科学和精英运动表现的进步，”<strong>Verséa Discovery 的联合创始人兼首席执行官 Sean Fetcho</strong> 表示。“我们与 10X Health 的合作将我们的技术整合到更广泛的精准健康生态系统中，确保结果不仅仅是提供信息——而是直接塑造个性化的优化策略。”</p>
</div><p>10X MitoScreen™ will be available in the first quarter 2026 as part of 10X Health System's expanding precision testing portfolio, supporting consumers, clinicians, and enterprise partners seeking deeper insight into human performance and longevity.</p>
<div class="lb-trans"><p>10X MitoScreen™将在 2026 年第一季度作为 10X Health System 不断扩展的精准测试组合的一部分提供，支持寻求对人类表现和长寿有更深入洞察的消费者、临床医生和企业合作伙伴。</p>
</div><p>Early access to the test via Verséa Discovery's mescreenTM technology can be done now by going to https://mitoscreen.com</p>
<div class="lb-trans"><p>通过 Verséa Discovery 的 mescreenTM 技术，现在可以提前访问该测试，访问 https://mitoscreen.com</p>
</div><p><strong>ABOUT 10X HEALTH SYSTEM</strong> 10X Health System is a precision wellness company redefining how people understand, optimize, and take control of their health. Founded on the belief that no two individuals are the same, 10X Health replaces one-size-fits-all approaches with data-driven insight, using advanced genetic testing, blood analysis, and emerging diagnostics to uncover the root causes behind performance, energy, and long-term health outcomes.</p>
<div class="lb-trans"><p><strong>关于 10X HEALTH SYSTEM</strong> 10X Health System 是一家精准健康公司，重新定义人们如何理解、优化和掌控自己的健康。基于没有两个个体是相同的信念，10X Health 用数据驱动的见解取代一刀切的方法，利用先进的基因测试、血液分析和新兴诊断来揭示表现、能量和长期健康结果背后的根本原因。</p>
</div><p>By translating complex biological data into clear, actionable recommendations across nutrition, supplementation, lifestyle, and clinical therapies, 10X Health empowers individuals and organizations to move from reactive care to proactive, personalized health optimization. Serving consumers, clinicians, and enterprise partners, the company is building a new standard for precision wellness - one where access to data creates clarity, confidence, and measurable impact on human performance and longevity.</p>
<div class="lb-trans"><p>通过将复杂的生物数据转化为清晰、可操作的营养、补充、生活方式和临床治疗建议，10X Health 使个人和组织能够从反应性护理转向主动、个性化的健康优化。该公司服务于消费者、临床医生和企业合作伙伴，正在建立精准健康的新标准——一个数据获取创造清晰度、自信和对人类表现和长寿产生可衡量影响的标准。</p>
</div><p><strong>ABOUT VERSÉA DISCOVERY</strong> Verséa Discovery, Inc. is a U.S.-based precision medicine company pioneering cellular and mitochondrial health technologies. Its proprietary <em>mescreen™</em> technology was first validated in advanced research settings and is now driving next-generation precision health insights to consumers, clinics and research institutions.</p>
<div class="lb-trans"><p><strong>关于 VERSÉA DISCOVERY</strong> Verséa Discovery, Inc.是一家总部位于美国的精准医学公司，开创了细胞和线粒体健康技术。其专有的_mescreen™_技术最初在先进的研究环境中得到验证，现在正在为消费者、诊所和研究机构提供下一代精准健康见解。</p>
</div><p>Photo - https://mma.prnewswire.com/media/2869561/Partnership.jpg</p>
<div class="lb-trans"><p>照片 - https://mma.prnewswire.com/media/2869561/Partnership.jpg</p>
</div><p>Logo - https://mma.prnewswire.com/media/2869342/10XHealth_Logo.jpg</p>
<div class="lb-trans"><p>标志 - https://mma.prnewswire.com/media/2869342/10XHealth_Logo.jpg</p>
</div><p>SOURCE 10X Health System; Verséa Discovery, Inc</p>
<div class="lb-trans"><p>来源 10X Health System; Verséa Discovery, Inc</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTI2Jk5ld3NJdGVtSWQ9TE43MDcwMyZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMjYxMTQxUFJfTkVXU19VU1BSX19fX19MTjcwNzAz" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LN70703&amp;Transmission_Id=202601261141PR_NEWS_USPR_____LN70703&amp;DateId=20260126"/></p>

11:41 ET
			
			
				10X Health System and Verséa Discovery Launch 10X MitoScreen™, a Next-Generation Mitochondrial Assessment Test

prnewswire

华夏上证科创板生物医药ETF

SunLink卫生系统

CS精准医

易方达沪深300医药ETF

国泰中证生物医药ETF

医药突破 ETF - ALPS

Sequoia Vaccines, Inc.

标普全球医疗股指数 ETF - iShares

基因改革 ETF - ARK

华夏医药ETF

纳斯达克生物科技指数 ETF - iShares Nasdaq

2 倍做多纳斯达克生物技术 ETF - ProShares

美国制药 ETF - iShares

生物科技 ETF - VanEck Vectors

医疗业 ETF - SPDR

生物科技ETF基金

标普生物技术 ETF - SPDR

动态生物技术与基因组 ETF - Invesco

纽交所高增长板生物技术指数 ETF - First Trust

10X Health System 和 Verséa Discovery 推出 10X MitoScreen™，这是一项新一代的线粒体评估测试